Adagene is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/01/25 | $25,000,000 | Strategic |
Sanofi | undisclosed |
